Appointments at Ricerca Biosciences, Trialytics, CeeTox and Firecrest Clinical – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Mds pharma services, Medicine, Management occupations, President of the united states

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Ricerca Biosciences, Trialytics, CeeTox and Firecrest Clinical.

Ricerca Biosciences ​has appointed Michael Placke ​as senior vice president and general manager of its facility in Concord, Ohio, US. Placke has more than 25 years of pharma and contract research experience at firms including Wyeth and Battelle Pharma.

Malcolm Bohm​ is to step down as president of Trialytics​ in June 2010. Bohm founded Trialytics and worked for 20 years as a pharmaceutical executive.

CeeTox ​has hired Phil Burton​ as director of ADME services. Burton was cofounder, CEO and chief scientific officer of ADMETRx before it decided to cease operations. CeeTox has hired a further seven former ADMETRx employees.

Alan Horgan ​has been named as CEO of Firecrest Clinical​. Horgan began working with Firecrest in 2009 having previously held positions at MDS Pharma Services and Covance.

WIL Research​ has appointed David Spaight ​as CEO. Spaight was previously president of MDS Pharma Services and has been involved with the Association of Clinical Research Organizations (ACRO) and Fisher Scientific Products.

David Julien ​is to retire as president, global supply chain at Sigma-Aldrich​. Joseph Porwoll​ has been promoted to VP, global supply chain to takeover the responsibilities held by Julien.

Delphi Genetics ​has reorganised its executive leadership, with Philippe Gabant ​becoming head of business development and Cedric Szpirer ​taking the role of CEO. Gabant and Szpirer cofounded the company with Michel Milinkovitch and the University of Brussels.

James Kearney ​has been appointed as director, client services at Qforma​. Kearney has 15 years of pharma experience at companies including EKR Therapeutics, Sandoz and Bristol-Myers Squibb.

Related topics: Markets & Regulations

Related news

Show more

Follow us


View more